Drug intelligence / Profile preview

docetaxel + 177Lu-PSMA-I&T

Development stage: Unknown
Lead developer: Instituto do Cancer do Estado de São Paulo
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

docetaxel + 177Lu-PSMA-I&T is a combination therapy being investigated for the treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). The combination consists of docetaxel, a taxane-based chemotherapy that inhibits microtubule depolymerization, and 177Lu-PSMA-I&T, a radioligand therapy. 177Lu-PSMA-I&T targets the prostate-specific membrane antigen (PSMA), which is highly expressed on prostate cancer cells, delivering localized beta-particle radiation (Lutetium-177) to the tumor cells and their microenvironment. This synergistic approach aims to enhance anti-tumor activity by combining systemic cytotoxic chemotherapy with targeted radiopharmaceutical delivery. The Instituto do Cancer do Estado de São Paulo is conducting a Phase I dose-escalation study to evaluate the safety and recommended Phase II dose of this combination.

Other names: 177Lu-DOTAGA-(I-y)fk(Sub-KuE)Lutetium (177Lu) PSMA-I&T

Targets

TUBB (Tubulin (alpha and beta subunits))DNAPSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on docetaxel + 177Lu-PSMA-I&T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + 177Lu-PSMA-I&T.

Explore the full profile